OBIO

Orchestra BioMed Holdings, Inc. (OBIO) | Rumor.io

Orchestra BioMed Holdings

OBIO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,957

Bullish sentiment (50-day avg)100%

Price to earnings ratio-5.31

Market capitalization354M

Earnings per share-0.83

Dividend yield (TTM)—

Revenue (annual)33.5M

Net income (annual)-52.7M

Social

What share of all stock conversation is about OBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 10

$OBIO upgraded by BTIG to Buy with a $10 price target, with a 5.32% gap higher and a short ratio of 6.69 highlighting a potential squeeze setup.
Orchestra BioMed is in an expected correction phase, with conference updates and trial progress updates causing short-term volatility, but a long-term stable anchor.
The market is still digesting recent meetings, trial progress updates, and insider activity, with the current price level seeming like a recalibration of "short-term visibility" rather than a sudden rewrite of the long-term narrative.

Generated by AI

Sentiment

Of the messages about OBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	97.59% +13.01
Bearish	—	0% 0	0% 0	2.41% -13.01

Bullish· Apr 22

$OBIO has a strong buy rating due to FDA breakthrough therapy designation, leading to a stock price surge.
The FDA has granted Breakthrough Device designation for AVIM therapy, tackling 7.7M+ patients with uncontrolled hypertension, with serious backing from a pivotal study with $MDT.
$OBIO's low float and fresh catalysts create a setup for a potential big pop, with the stock already up 19% premarket.

Bearish· Apr 22

$OBIO's price action is bearish, with a flat VWAP and light volume after the open, potentially leading to a drop to $3.50.
Shorting activity is strong on $OBIO, with a high number of shorts covering soon, which could lead to further price declines.
Despite positive news, $OBIO's market reaction has been negative, with the stock dropping on the day of the announcement and failing to hold its lows.

Generated by AI

Topics

Of the messages about OBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	87.5%	93.88%
Analysts	—	0%	12.5%	5.1%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	1.02%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	0%

Apr 22

Orchestra BioMed Holdings, Inc. ($OBIO) received FDA Breakthrough Device Designation for its AVIM therapy, targeting 7.7M patients with uncontrolled hypertension.
The FDA granted Breakthrough Device Designation for AVIM therapy, which is currently being evaluated in the BACKBEAT global pivotal study conducted by Orchestra BioMed in collaboration with Medtronic.
Orchestra BioMed shares surged on the news, with a premarket price increase of up to 32.04% to $3.75, and a market cap of $108.81M.

Generated by AI

Community

Of the messages about OBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	20%	22.86%	33.51%
Newcomers	—	80%	77.14%	66.49%

Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

8d agoYahoo Finance

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyondNEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced

13d agoYahoo! Finance Canada

Orchestra BioMed receives $6.1m milestone from Vivasure deal

14d agoInvesting.com

Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of Vivasure

15d agoYahoo Finance

B. Riley Adjusts Orchestra BioMed Price Target to $11 From $10, Maintains Buy Rating

Orchestra BioMed Holdings (OBIO) has an average rating of buy and mean price target of $12, accordin

15d agoYahoo Finance

Orchestra BioMed at Wells Fargo: partnership model in focus

19d agoInvesting.com

Also Discussed

Investors talking about OBIO also mention

#	Name	Attention
1	Rein Therapeutics Inc.RNTX	0%0
2	GCL Global Holdings LtdGCL	0%0
3	Immix Biopharma, Inc.IMMX	0.03%+0.03
4	MOND - Mondee Holdings, Inc.	——
5	Ainos, Inc.AIMD	0%+0
6	CleanCore Solutions Inc. Class B Common StockZONE	0%+0
7	Envoy Medical Inc Class A Common StockCOCH	0%0
8	Veea Inc.VEEA	0%0
9	Bridger Aerospace Group Holdings, Inc.BAER	0%+0
10	Gain Therapeutics, Inc.GANX	0.04%+0.02

Orchestra BioMed Holdings, Inc.

Healthcare
Biotechnology

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing therapeutic technologies for cardiovascular disease and related medical conditions. Its current portfolio centers on AVIM Therapy, a bioelectronic treatment candidate designed to help lower blood pressure in patients with pacemakers, and Virtue Sirolimus AngioInfusion Balloon, a drug-device platform intended for treating atherosclerotic artery disease. The company also works on cardiac neuromodulation programs and minimally invasive device technologies that support interventional procedures. Orchestra BioMed’s business model relies on partnerships with established medical device companies to advance clinical development and commercialization. Headquartered in New Hope, Pennsylvania, Orchestra BioMed plays a niche role in the medical technology market by combining device innovation, bioelectronic therapy, and targeted drug delivery within cardiovascular care.

Website

Location

150 Union Square Drive

New Hope, PA, 18938

United States

Social

What share of all stock conversation is about OBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 10

$OBIO upgraded by BTIG to Buy with a $10 price target, with a 5.32% gap higher and a short ratio of 6.69 highlighting a potential squeeze setup.
Orchestra BioMed is in an expected correction phase, with conference updates and trial progress updates causing short-term volatility, but a long-term stable anchor.
The market is still digesting recent meetings, trial progress updates, and insider activity, with the current price level seeming like a recalibration of "short-term visibility" rather than a sudden rewrite of the long-term narrative.

Generated by AI

Sentiment

Of the messages about OBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	97.59% +13.01
Bearish	—	0% 0	0% 0	2.41% -13.01

Bullish· Apr 22

$OBIO has a strong buy rating due to FDA breakthrough therapy designation, leading to a stock price surge.
The FDA has granted Breakthrough Device designation for AVIM therapy, tackling 7.7M+ patients with uncontrolled hypertension, with serious backing from a pivotal study with $MDT.
$OBIO's low float and fresh catalysts create a setup for a potential big pop, with the stock already up 19% premarket.

Bearish· Apr 22

$OBIO's price action is bearish, with a flat VWAP and light volume after the open, potentially leading to a drop to $3.50.
Shorting activity is strong on $OBIO, with a high number of shorts covering soon, which could lead to further price declines.
Despite positive news, $OBIO's market reaction has been negative, with the stock dropping on the day of the announcement and failing to hold its lows.

Generated by AI

Topics

Of the messages about OBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	87.5%	93.88%
Analysts	—	0%	12.5%	5.1%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	1.02%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	0%

Apr 22

Orchestra BioMed Holdings, Inc. ($OBIO) received FDA Breakthrough Device Designation for its AVIM therapy, targeting 7.7M patients with uncontrolled hypertension.
The FDA granted Breakthrough Device Designation for AVIM therapy, which is currently being evaluated in the BACKBEAT global pivotal study conducted by Orchestra BioMed in collaboration with Medtronic.
Orchestra BioMed shares surged on the news, with a premarket price increase of up to 32.04% to $3.75, and a market cap of $108.81M.

Generated by AI

Community

Of the messages about OBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	20%	22.86%	33.51%
Newcomers	—	80%	77.14%	66.49%

Orchestra BioMed Holdings

Social

Sep 10

Sentiment

Bullish· Apr 22

Bearish· Apr 22

Topics

Apr 22

Community

News

Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

Orchestra BioMed receives $6.1m milestone from Vivasure deal

Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of Vivasure

B. Riley Adjusts Orchestra BioMed Price Target to $11 From $10, Maintains Buy Rating

Orchestra BioMed at Wells Fargo: partnership model in focus

Also Discussed

Orchestra BioMed Holdings, Inc.

Company Information

Location

News

Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

Orchestra BioMed receives $6.1m milestone from Vivasure deal

Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of Vivasure

B. Riley Adjusts Orchestra BioMed Price Target to $11 From $10, Maintains Buy Rating

Orchestra BioMed at Wells Fargo: partnership model in focus

Also Discussed

Social

Sep 10

Sentiment

Bullish· Apr 22

Bearish· Apr 22

Topics

Apr 22

Community